UroToday5d
Navigating Focal Therapy for Prostate Cancer: Contemporary Perspectives and Future Trajectories in the Canadian Context - Beyond the Abstract
Over the past decade, prostate cancer treatment has increasingly shifted towards less invasive approaches that prioritize preserving patients' quality of life. Among these, various focal therapy ...
UroToday5d
Secondary Bladder Cancer Risk and Long-Term Adverse Effects after Radiotherapy for Prostate Cancer - Expert Commentary
The long-term impact of localized prostate cancer treatments on secondary bladder cancer is an important area of study. A recent cohort study by Unger et al. examined secondary bladder cancer ...
UroToday4d
The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease.
There is a growing understanding of the oligometastatic disease state, characterized by the presence of 5 or fewer lesions. Advanced molecular imaging techniques, such as prostate-specific membrane ...
UroToday4d
Deescalated 225Ac-PSMA-617 Versus 177Lu/225Ac-PSMA-617 Cocktail Therapy: A Single-Center Retrospective Analysis of 233 Patients.
The aim of this work is to evaluate our clinical real-world data obtained with 225Ac-PSMA-617 (AcPSMA), which were acquired under compassionate care regulations in patients with advanced-stage ...
UroToday6d
Of HIFs and hERVs: Neoantigen generation in kidney cancer.
New evidence published in Cell provides insight into the interplay between hypoxia-inducible factor activity and downstream neoantigen production in clear cell renal cell carcinoma (ccRCC). Jiang et ...
UroToday6d
Point-of-Care Diagnosis of Early-Stage Bladder Cancer Using Urine Samples - Expert Commentary
Bladder cancer detection relies on invasive cystoscopy and urine cytology, which have several limitations in early diagnosis and frequent monitoring, especially in low-resource settings. A recent ...
UroToday5d
CD44 Methylation Levels in Androgen-Deprived Prostate Cancer: A Putative Epigenetic Modulator of Tumor Progression.
Epigenetic changes have been reported to promote the development and progression of prostate cancer (PCa). Compared to normal prostate tissue, tumor samples from patients treated with ...
UroToday6d
Deciphering the Transcription Factor Landscape in Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation.
Prostate cancer (PCa) stands as a leading cause of cancer-related mortality among men, with treatment-induced neuroendocrine prostate cancer (NEPC) posing a challenge as an ARPI-resistant subtype. The ...
UroToday6d
Etiology of Prostate Cancer with the TMPRSS2:ERG Fusion: A Systematic Review of Risk Factors - Beyond the Abstract
TMPRSS2:ERG is the most common gene fusion in prostate cancer. Approximately 140,000 men in the United States are diagnosed with prostate cancer that has the TMPRSS2:ERG gene fusion annually, out of ...
UroToday5d
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US.
The treatment landscape of metastatic clear cell renal cell carcinoma (ccRCC) has rapidly evolved with the approval of multiple immune checkpoint inhibitor (ICI)-based combinations. However, clinical ...
UroToday6d
Clear cell renal cell carcinoma molecular subtypes differ by African and European genetic similarity groups.
Self-reported Black (B) individuals remain underrepresented in molecular studies of clear cell renal cell carcinoma (ccRCC) relative to White (W) individuals. We performed whole-exome and ...
UroToday6d
Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer.
Combination treatment with Enfortumab vedotin (EV), an antibody drug conjugate targeting Nectin-4 with a monomethyl auristatin E (MMAE) payload, and pembrolizumab, a programmed death 1 (PD-1) ...